Scarica l'app Stockscreener
0.00
100.00%
-0.037
Precedente Chiudi:
$0.037
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-92.59%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
Nome
Nkgen Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NKGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nkgen Biotech Inc Borsa (NKGN) Ultime notizie
NKGen Biotech Secures New Promissory Note Financing - TipRanks
NKGen Biotech issues statement on NKGen Korea board appointments - MSN
Financial Review: Alpha Cognition (OTC:ACOGF) vs. NKGen Biotech (NYSE:NKGN) - Defense World
Analyzing Genocea Biosciences (NASDAQ:GNCA) and NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech, Inc. Issues Statement on Recent Board - GlobeNewswire
NKGen Biotech (OTC: NKGN) backs new NKGen Korea board for Asia NK cell growth - Stock Titan
Is NKGen Biotech, Inc. technically bullish or bearish? - Markets Mojo
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKMAX CO., Ltd. has Changed its Name to NKGen Korea - marketscreener.com
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review - Defense World
Sorrento Therapeutics (OTCMKTS:SRNEQ) & NKGen Biotech (NYSE:NKGN) Head-To-Head Review - Defense World
Reviewing NKGen Biotech (NYSE:NKGN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Total debt per share of NKGen Biotech Inc. – OTC:NKGN - TradingView
Revenue per share of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech, Inc. (NKGN) Eps Diluted (Quarterly) - Zacks Investment Research
Nkgen Biotech’s Promising Alzheimer’s Study: A Potential Game-Changer? - TipRanks
NKGen Biotech Secures $2.5M in Stock Purchase Agreement - MSN
NKGen Biotech, Inc. (NKGNW) Stock Price, News, Quote & History - Yahoo
NKGen Biotech, Inc. (NKGNW) stock price, news, quote and history - Yahoo
NKGen Biotech provides clarification on quotation display, trading status - MSN
NKGen Biotech, Inc. (NKGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
NKGen Biotech, Inc. (NKGN) Company Profile & Facts - Yahoo
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - The Manila Times
Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan
NKGen Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
NKGen Biotech, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - The Manila Times
NKGen to Present Troculeucel for Alzheimer's at WCN Oct 15 | NKGN Stock News - Stock Titan
NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World
NKGen Biotech Announces Consulting Agreement with Dr. Kim - MSN
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors - Investing.com Nigeria
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors By Investing.com - Investing.com South Africa
NKGen Biotech CEO to present NK cell therapy data at China forum - Investing.com Australia
Breakthrough NK Cell Therapy for Neurodegenerative Diseases: NKGen Biotech Presents Latest Clinical Data - Stock Titan
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum - Yahoo Finance
LadRx (OTCMKTS:CYTR) & NKGen Biotech (NYSE:NKGN) Head-To-Head Analysis - Defense World
NKGen Biotech announces completion of NKMax acquisition - MSN
NKGen Biotech Acquires Majority Stake in NKMax - TipRanks
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire
$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN
NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World
NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire
Nkgen Biotech Inc Azioni (NKGN) Dati Finanziari
Non sono disponibili dati finanziari per Nkgen Biotech Inc (NKGN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Capitalizzazione:
|
Volume (24 ore):